<table>
<tr><th>Reference and country</th><th>Study type and period</th><th>Study quality</th><th>Number of patients</th><th>Patient characteristics</th><th>Intervention</th><th>Comparison</th><th>Length of follow-up</th><th>Outcomes</th><th>Source of funding</th><th>Additional comments</th></tr>
<tr>
<td>Maiche 1993 Eur J Cancer. 1993;29A(10):1403-5.</td>
<td>RCT.</td>
<td>No mention of allocation concealment or blinding</td>
<td>59 (92 courses of chemotherapy</td>
<td>Adult patients with lymphoma or solid tumours who had earlier developed an infection following antineoplastic chemotherapy</td>
<td>G-CSF plus quinolone (ofloxacin or ciprofloxacin)</td>
<td>G-CSF alone</td>
<td>Not reported – outcomes were assessed over the course of chemotherapy.</td>
<td>Documented infection rate (per course of chemotherapy)
<table><tr><th></th><th>n</th><th>N</th></tr><tr><td>G-CSF + ABX</td><td>6</td><td>44</td></tr><tr><td>G-GCSF</td><td>15</td><td>48</td></tr></table>
Microbiologically documented infection rate (per course of chemotherapy)
<table><tr><th></th><th>n</th><th>N</th></tr><tr><td>G-CSF + ABX</td><td>2</td><td>44</td></tr><tr><td>G-GCSF</td><td>9</td><td>48</td></tr></table>
Duration of leukopenia (<1.0 X 10^9/l)
<table><tr><th></th><th>Median (range)</th></tr></table></td>
<td>Not reported</td>
<td>Inconsistency between numbers in the text and tables 1. Figures from tables 1 used</td>
</tr>
</table>

Reference and country	Study type and period	Study quality	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcomes	Source of funding	Additional comments
								G-CSF + ABX 3.5 days(1-7) **G-GCSF** 4 days (1 - ∞)		
Leonard et al (2009)	RCT. 2001 to 2007	Allocation concealment adequate (according to protocol). No blinding	407	Adult patients with breast cancer and neutropenia (ANC < 1.5 X 10^9/l) or hospitalisation due to neutropenia	G-CSF (filgrastim or pegfilgrastim) as secondary prophylaxis	No G-CSF (chemotherapy dose reduction or delay)	Outcomes measured after each cycle and at the end of chemotherapy.. Long term follow up for overall survival (10 years).	**Neutropenia** proportion of patients with neutropenic events – hospitalization due to neutropenia (ANC < 1.5 X 10^9/l) or ANC low enough to require treatment delay or ≥15% dose reduction **G-CSF** n=36 N=204 **No G-GCSF** n=132 N=203 **Relative dose intensity** proportion of patients who received at least 85% of the planned RDI.	Amgen	Abstract only, trial protocol also used.

<table>
<tr><th>Reference and country</th><th>Study type and period</th><th>Study quality</th><th>Number of patients</th><th>Patient characteristics</th><th>Intervention</th><th>Comparison</th><th>Length of follow-up</th><th>Outcomes</th><th>Source of funding</th><th>Additional comments</th></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>
<table>
<tr><th></th><th>n</th><th>N</th></tr>
<tr><td>G-CSF</td><td>155</td><td>204</td></tr>
<tr><td>No G-GCSF</td><td>91</td><td>203</td></tr>
</table>
Relative dose intensity (pegfilgrastim vs filgrastim) non-randomised comparison.
<table>
<tr><th></th><th>n</th><th>N</th></tr>
<tr><td>PEG</td><td>64</td><td>75</td></tr>
<tr><td>Filgrastim</td><td>91</td><td>129</td></tr>
</table>
</td><td></td><td></td></tr>
</table>